Table 2.
Clinical and pathological characteristics of patients with an EGFR mutant tumor versus patients with an ALK positive tumor
| Characteristic | EGFR+ | ALK+ | P-value |
|---|---|---|---|
| Gender, N (%) | |||
| Female | 46 (69.7) | 23 (56.1) | |
| Male | 20 (30.3) | 18 (43.9) | 0.212 |
| Smoking status, N (%) | |||
| Never | 48 (72.7) | 26 (63.4) | |
| Former | 6 (9.1) | 5 (12.2) | |
| Current | 12 (18.2) | 10 (24.4) | 0.601 |
| Mean age, (SD) | 60.2 (8.7) | 54.8 (9.1) | 0.003 |
| Mean CEA (ug/l), (SD) | 14.4 (28.5) | 10.3 (27.4) | 0.462 |
| Histology, N (%) | |||
| MIA | 1 (1.5) | 0 (0.0) | |
| Lepidic adenocarcinoma | 18 (27.3) | 1 (2.4) | |
| Acinar adenocarcinoma | 30 (45.5) | 15 (36.6) | |
| Papillary adenocarcinoma | 6 (9.1) | 2 (4.9) | |
| Micropapillary adenocarcinoma | 2 (3.0) | 2 (4.9) | |
| Solid adenocarcinoma | 7 (10.6) | 16 (39.0) | |
| IMA | 2 (3.0) | 5 (12.2) | < 0.001 |
| Lepidic, N (%) | |||
| absent | 25 (37.9) | 37 (90.2) | |
| present | 41 (62.1) | 4 (9.8) | < 0.001 |
| Acinar, N (%) | |||
| absent | 15 (22.7) | 17 (41.5) | |
| present | 51 (77.3) | 24 (58.5) | 0.040 |
| Papillary, N (%) | |||
| absent | 52 (78.8) | 35 (85.4) | |
| present | 14 (21.2) | 6 (14.6) | 0.396 |
| Micropapillary, N (%) | |||
| absent | 28 (42.4) | 23 (56.1) | |
| present | 38 (57.6) | 18 (43.9) | 0.169 |
| Solid, N (%) | |||
| absent | 50 (75.8) | 21 (51.2) | |
| present | 16 (24.2) | 20 (48.8) | 0.009 |
| Mucinous, N (%) | |||
| absent | 59 (89.4) | 36 (87.8) | |
| present | 7 (10.6) | 5 (12.2) | 1.000 |
| Pathological stage, N (%) | |||
| Ia | 20 (30.3) | 6 (14.6) | |
| Ib | 13 (19.7) | 2 (4.9) | |
| IIa | 6 (9.1) | 8 (19.5) | |
| IIb | 0 (0.0) | 1 (2.4) | |
| IIIa | 19 (28.8) | 15 (36.6) | |
| IIIb | 2 (3.0) | 6 (14.6) | |
| IV | 6 (9.1) | 3 (7.3) | 0.0071 |
Abbreviations: MIA, minimally invasive adenocarcinoma; IMA, invasive mucinous adenocarcinoma
Bolded values indicate a statistically significant result
1
P value was derived by combing Ia and Ib, IIa and IIb, and IIIa and IIIb